Conflation of dosing regimen with efficacy at issue in Bayer appeal in US
Germany’s Bayer Pharma Aktiengesellschaft and Mylan Pharmaceuticals are set to square off at the US Court of Appeals for the Federal Circuit tomorrow morning over findings by the Patent Trial and...To view the full article, register now.
Already a subscriber? Click here to view full article